Virginia Tech Researchers Designing Light-Activated Molecules As New Anticancer Drugs

April 15, 1997

BLACKSBURG, VA -- Virginia Tech faculty members Karen Brewer in chemistry and Brenda Shirley in biology, and their students, are building new molecules to act as anticancer agents.

The aim is to develop molecular systems to counter cancer's ability to develop immunity to anticancer drugs and to help physicians focus their attack on cancer cells.

"We are building a new type of molecule that binds to DNA in new and different ways," says Brewer. "Tumors develop resistance to drug systems by changing or eliminating sites where drugs have been able to attach to the tumor. By changing the shape and the size of the molecule carrying the drug and the way the drug binds to DNA, we can continue to design systems that are effective against resistant tumor lines."

Early screening of the new molecules by the National Cancer Institute show that the new molecules do bind to the target DNA and have some anticancer activity, Brewer reports. The next steps are to increase the activity and introduce photoinitiation. The group will present news of their advances on these goals during the American Chemical Society meeting in San Francisco April 13-17.

Anticancer drugs such as chemotherapy often make people sick because, while the drugs are killing cancer cells, they are also damaging healthy cells.

Brewer, Shirley, and their students are designing drugs that would become active only when hit by light. Surgery would not be required because a low-level laser would deliver light in the near-infrared range through the skin to the tumor site. The light would activate the engineered molecules to bind to the DNA of the cancer cells and deliver killing drugs.

Virginia Tech graduate student Matthew Milkevitch delivered a paper on "Photochemical and DNA binding studies of platinum-ruthenium bimetallic compounds," on Sunday, April 13. Co-authors are Brewer, Shirley and undregraduate students Eric Brauns and Hannah Storrie.

The research is supported by the Jeffress Memorial Trust and the Virginia Tech Pilot Research Program.

## 97096##

Virginia Tech

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to